Luye Pharma (HKG:2186) said it enrolled the first patient in a Phase 2 clinical trial in China for its investigational drug LY03017, according to a Wednesday Hong Kong bourse filing.
Shares of the pharma company fell over 2% in late-morning trade Thursday.
The drug is being tested for the treatment of psychosis associated with Alzheimer's disease.